Navigation Links
Aptuit Drug Discovery & Development Center In Verona, Italy Hits 100th Client Milestone
Date:11/8/2012

GREENWICH, Conn., Nov. 8, 2012 /PRNewswire/ -- Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the number of clients placing work at The Aptuit Center for Drug Discovery & Development in Verona, Italy has reached 100, giving the site a strong vote of confidence from the marketplace.

(Logo:  http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )

Mark Hembarsky, Vice President and Site Leader of the facility stated, "We are excited to have reached this important milestone of 100 clients at Aptuit Verona. In July of 2010, we started with one client, GlaxoSmithKline, following our acquisition of the site from them. Since that time, more and more clients have been recognizing that we have something unique and valuable to offer, and that we are certainly doing something right in helping them achieve their goals."

Mr. Hembarsky explained that in the two brief years since the acquisition, the Aptuit Verona facility has successfully made the transition from a single customer site to a dynamic drug discovery and development center attracting all types of clients – large, multinational pharmaceutical innovators, midsize and small pharma companies, biotechs and startups.

"Companies from the EU, North America, Asia and South America have placed projects with us covering numerous therapeutic areas," said Mr. Hembarsky. "We are proud that industry-leading companies like Pfizer Inc., Chiesi Farmaceutici, Sunovion Pharmaceuticals Inc., Boehringer Ingelheim, UCB, C10 Pharma, Autifony Therapeutics and GlaxoSmithKline are among the clients that have chosen to partner with Aptuit." He added that most clients have subsequently contracted repeat business with Aptuit and many have requested proposals for additional work before their initial project was completed.

"Our growth is a testimony to Aptuit's capabilities, and continued business inquiries are a source of great encouragement. Clients recognize that we offer the intelligence and insights of scientific professionals engaged in multidisciplinary activities, from integrated discovery, preclinical development, API and drug product development and clinical sciences through to clinical Proof of Concept.  Our 'heads for science' are accustomed to taking a big picture approach, applying what we call Integrated Knowledge. Because of our legacy as an R&D engine of a leading pharmaceutical company, we understand the total process of drug discovery and development and we apply that understanding to all work that we perform – whether it's fully integrated services or a specific stand-alone project. Our teams of highly experienced and knowledgeable drug development professionals can anticipate potential problems and offer preemptive solutions, allowing clients to mitigate risks, save time and reduce costs. Our 'hearts for service' are devoted to understanding what is important to each project and delivering, as promised, on time and in full, ultimately helping each client achieve their goals," said Mr. Hembarsky.

Mr. Needleman concluded, "We are very pleased that clients understand that they are getting the best of both worlds when they work with Aptuit Verona – the efficiency of an experienced CRO combined with the scientific expertise of a large pharmaceutical research and development engine. We're now at 100, and still counting."

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGOO (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

CONTACT:  Maria Garvey, +1-1-914-747-1400, maria@delfino.com

 


'/>"/>
SOURCE Aptuit
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Del Mar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference
2. Discovery Labs Reports Third Quarter 2012 Financial Results
3. BD Completes Sale of Majority of Discovery Labware Unit
4. Discovery of New "Youth Pill" Revealed At International Scientific Conference
5. Drug Discovery in Rare Diseases
6. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
7. Initiating Rare Disease Drug Discovery Projects
8. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
9. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
10. Drug Discovery Technologies, BCC Research
11. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/18/2017)... DUBLIN , Feb. 17, 2017 Research and ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Latin America ... for the period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/17/2017)... -- According to a new market research report "Particle ... (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare Industry, ... market is expected to reach USD 330.6 Million by 2021 from ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... ... ReportingMD, a Population Health Software Company, is pleased to announce a move to a larger ... triple the size of the previous location while bringing life back to a medical practice ... “We are excited to expand our footprint to better serve our growing client base. ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism ... event at Chuck E. Cheese’s locations throughout New England, New York and New Jersey ... to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... The Citadel’s ... undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged by ... operations of the nursing department in early 2016. After a nation-wide search, she was ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" ... and MEDfx and the Delaware Health Information Network (DHIN) have partnered to improve ... first state-wide health information exchange, DHIN stores and shares real-time health data for ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
Breaking Medicine News(10 mins):